[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630298":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":37,"centralContacts":41,"locations":50,"responsibleParty":64,"collaborators":28,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":28,"enrollmentInfo":77,"targetDuration":28,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":28,"overallStatus":52,"whyStopped":28,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Asan Medical Center","OTHER",[8,13,18],{"label":9,"type":10,"description":9,"interventionNames":11},"Standard dose Influenza vaccine","ACTIVE_COMPARATOR",[12],"Biological: Standard-dose trivalent inactivated influenza vaccine (SD-IIV3)",{"label":14,"type":15,"description":14,"interventionNames":16},"High dose influenza vaccine","EXPERIMENTAL",[17],"Biological: High-dose trivalent inactivated influenza vaccine (HD-IIV3)",{"label":19,"type":15,"description":19,"interventionNames":20},"MF.59 adjuvant influenza vaccine",[21],"Biological: MF59-adjuvanted quadrivalent inactivated influenza vaccine (aIIV4)",[23,29,33],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"BIOLOGICAL","High-dose trivalent inactivated influenza vaccine (HD-IIV3)","High-dose trivalent inactivated influenza vaccine containing 60 µg hemagglutinin per strain (4× standard dose). Single intramuscular injection administered during the influenza season.",[14],null,{"type":24,"name":30,"description":31,"armGroupLabels":32,"otherNames":28},"MF59-adjuvanted quadrivalent inactivated influenza vaccine (aIIV4)","MF59C.1 squalene-based adjuvanted quadrivalent inactivated influenza vaccine containing 15 µg hemagglutinin per strain. Single intramuscular injection administered during the influenza season.",[19],{"type":24,"name":34,"description":35,"armGroupLabels":36,"otherNames":28},"Standard-dose trivalent inactivated influenza vaccine (SD-IIV3)","Standard-dose trivalent inactivated influenza vaccine containing 15 µg hemagglutinin per strain. Single intramuscular injection administered during the influenza season. Active comparator.",[9],[38],{"name":39,"affiliation":5,"role":40},"Sung-Han Kim, MD, PhD","PRINCIPAL_INVESTIGATOR",[42,47],{"name":43,"role":44,"phone":45,"phoneExt":28,"email":46},"So Yun Lim, MD, PhD","CONTACT","+82-10-4120-3816","soyun_lim@amc.seoul.kr",{"name":39,"role":44,"phone":48,"phoneExt":28,"email":49},"+82-2-3010-3305","shkimmd@amc.seoul.kr",[51],{"facility":5,"status":52,"city":53,"state":28,"zip":28,"country":54,"countryCode":28,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"RECRUITING","Seoul","South Korea",{"type":56,"coordinates":57},"Point",[58,59],126.9784,37.566,{"lat":59,"lon":58},[62],{"name":43,"role":44,"phone":63,"phoneExt":28,"email":46},"+82-2-3010-3261",{"type":40,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"Sung-Han Kim","Professor","100630298","phase-3-influenza-vaccination-strategy-for-patients-with-hematologic-malignancy-100630298",false,"NCT07485855","Influenza Vaccination Strategy for Patients With Hematologic Malignancy","Comparison of Immunogenicity of Different Influenza Vaccines in Patients With Hematologic Malignancies","(HEM-FLU)","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Confirmed diagnosis of hematologic malignancy, including:\n\nnon-Hodgkin lymphoma, Hodgkin lymphoma, acute leukemia, chronic leukemia, or plasma cell disorders\n\nExclusion Criteria:\n\n* Difficulty with repeated venipuncture or blood sampling (e.g., poor vascular access or bleeding tendency)\n* Cognitive or psychiatric impairment precluding understanding of or cooperation with study procedures\n* Known hypersensitivity to influenza vaccine components\n* Influenza vaccination within the preceding 6 months\n* Any other condition deemed clinically inappropriate for study participation at investigator discretion","ALL","19 Years",{"count":78,"type":79},60,"ESTIMATED","INTERVENTIONAL",[82],"PHASE3","This randomized controlled trial evaluates and compares the immunogenicity of three different influenza vaccine formulations: high-dose trivalent (HD-IIV3), MF59-adjuvanted quadrivalent (aIIV4), and standard-dose trivalent (SD-IIV3) vaccines. The study population consists of patients with hematologic malignancies, including those undergoing autologous stem cell transplantation or CAR-T cell therapy. The primary goal is to identify which vaccine strategy elicits the most robust antibody and T cell-mediated immune responses in this severely immunocompromised population",[85,86,87],"Hematologic Neoplasms","Influenza","Immunogenicity","2026-03-20",{"date":90,"type":91},"2026-03-24","ACTUAL",{"date":93,"type":91},"2025-12-04",{"date":95,"type":79},"2028-04-30",{"name":5,"class":6},1]